Published in Gene Therapy Weekly, March 25th, 1996
The therapeutic use of oligonucleotides as sense and antisense agents holds much promise as well as posing many problems. Antisense oligonucleotides have been used to inhibit viral as well as cellular gene expression. Unfortunately, they easily undergo nucleolytic degradation and are sensitive to exonucleases.
Phosphorothioate oligonucleotides are primarily degraded at the 3'-end. Several stabilization methods have been attempted, including chemical substitutes at the 3'-hydroxyl groups and creating oligonucleotides containing a hairpin loop...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.